Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 5/20 | 0.51 |
| ▸ | SELL | P14151 | 3/20 | 0.51 |
| ▸ | SELP | P16109 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1087728 | 0.84 | PLA2G2C (0.47) | SELESELLSELPMAPK1PLA2G2C | |
| SCHEMBL19079115 | 0.80 | MAPK1 (0.47) | SELESELLSELPMAPK1CETP | |
| SCHEMBL19079114 | 0.79 | MAPK1 (0.46) | SELESELLSELPMAPK1PLA2G2C | |
| SCHEMBL9019252 | 0.79 | CETP (0.56) | SELESELLSELPMAPK1CETP | |
| SCHEMBL9019200 | 0.79 | CETP (0.56) | SELESELLSELPMAPK1CETP | |
| SCHEMBL9019182 | 0.79 | CETP (0.56) | SELESELLSELPMAPK1CETP | |
| SCHEMBL9019248 | 0.79 | CETP (0.56) | SELESELLSELPMAPK1CETP | |
| SCHEMBL9019195 | 0.79 | CETP (0.56) | SELESELLSELPMAPK1CETP | |
| SCHEMBL9019272 | 0.79 | CETP (0.56) | SELESELLSELPMAPK1CETP | |
| SCHEMBL9019250 | 0.79 | CETP (0.56) | SELESELLSELPMAPK1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153615-B2 | Synthesis of glycerolipid carbamates and dicarbamates and their use as an antitumor compounds | THE UNIVERSITY OF MANITOBA (CA) | 2012-04-10 | — | — | US | disclosed |
| US-20090042811-A1 | Synthesis of Glycerolipid Carbamates and Dicarbamates and Their Use as an Antitumor Compounds | THE UNIVERSITY OF MANITOBA (CA) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042811-A1 | Synthesis of Glycerolipid Carbamates and Dicarbamates and Their Use as an Antitumor Compounds | PHOSPHO1, SGMS1, UGCG | SELE 4116/4885SELL 4124/4885SELP 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.